Zydus Lifesciences Receives USFDA Approval for Generic Ascorbic Acid Injection
Zydus Lifesciences has received final approval from the US Food and Drug Administration for its generic ascorbic acid injection, used primarily for short-term treatment of scurvy in patients aged five months and older when oral administration is not feasible. The USFDA designated the drug as a Competitive Generic Therapy, potentially granting 180-day market exclusivity. The product will be manufactured at Zydus's USFDA-approved plant in Gujarat and marketed in the US by Zydus Pharmaceuticals (USA) Inc. The branded version had annual sales of about USD 11.6 million.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (53/100). Lens Score 38/100.
Outlets measured: economictimes, news18, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 21 Aug, 09:37 am. Other outlets followed.